Profile data is unavailable for this security.
About the company
Oxford Biomedica PLC is a contract development and manufacturing organization (CDMO) in cell and gene therapy. It provides viral vector development and manufacturing expertise in lentivirus, adeno-associated virus (AAV), adenovirus and other viral vector types. It offers several technologies for viral vector manufacturing, including a 4th generation lentiviral vector system (the Tetravecta system), dual plasmid system for AAV production, suspension and perfusion process using process enhancers and stable producer and packaging cell lines. It has bioprocessing and manufacturing facilities across Oxfordshire, United Kingdom, Lyon and Strasbourg, France and near Boston, MA, United Sates. Its Platform segment is involved in bioprocessing and process development activities undertaken for third parties. Its Viral Vector includes LentiVector platform, inAAVate platform, and Other Viral Vectors. Its LentiVector platform technology is an advanced lentiviral vector-based gene delivery system.
- Revenue in GBP (TTM)97.28m
- Net income in GBP-142.02m
- Incorporated1996
- Employees834.00
- LocationOXBWindrush Court, Transport WayOXFORD OX4 6LTUnited KingdomGBR
- Phone+44 186 578 3000
- Fax+44 186 578 3001
- Websitehttps://www.oxb.com/
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Futura Medical PLC | 8.40m | -3.75m | 100.75m | 12.00 | -- | 12.82 | -- | 12.00 | -0.0126 | -0.0126 | 0.0272 | 0.0259 | 0.8538 | 5,710.27 | 7.20 | 699,850.80 | -38.14 | -79.25 | -47.43 | -127.22 | 67.70 | -- | -44.68 | -914.37 | 3.75 | -- | 0.00 | -- | -- | -- | -11.40 | -- | 219.68 | -- |
| Scancell Holdings Plc | 0.00 | -5.86m | 134.79m | 61.00 | -- | -- | -- | -- | -0.0068 | -0.0068 | 0.00 | -0.0038 | 0.00 | -- | -- | 0.00 | -23.24 | -31.66 | -32.48 | -37.66 | -- | -- | -- | -822.37 | -- | -- | 1.21 | -- | -100.00 | -- | 50.91 | -- | 131.54 | -- |
| Faron Pharmaceuticals Oy | 0.00 | -26.30m | 148.85m | 34.00 | -- | 129.72 | -- | -- | -0.3161 | -0.3161 | 0.00 | 0.011 | 0.00 | -- | -- | 0.00 | -130.90 | -213.06 | -443.92 | -963.12 | -- | -- | -- | -- | -- | -5.99 | 0.9022 | -- | -- | -- | -7.71 | -- | -16.05 | -- |
| hVIVO PLC | 64.38m | 17.45m | 155.81m | 274.00 | 9.07 | 4.05 | 7.54 | 2.42 | 0.0252 | 0.0252 | 0.0932 | 0.0565 | 0.9242 | -- | 4.25 | 234,974.50 | 25.04 | -0.643 | 46.68 | -1.29 | -- | -- | 27.10 | -0.765 | 1.60 | -- | 0.2530 | -- | 15.61 | 35.40 | 2,176.68 | -- | 136.55 | -- |
| 4Basebio PLC | 596.00k | -9.84m | 166.54m | -- | -- | -- | -- | 279.43 | -0.7843 | -0.7843 | 0.0476 | -0.4075 | 0.0508 | 0.6453 | 10.64 | -- | -83.78 | -- | -97.43 | -- | 69.63 | -- | -1,650.67 | -- | 2.53 | -18.44 | 1.51 | -- | 88.81 | -- | -48.83 | -- | -- | -- |
| Avacta Group Plc | 22.62m | -25.89m | 171.73m | 154.00 | -- | 3.49 | -- | 7.59 | -0.0867 | -0.0867 | 0.075 | 0.1334 | 0.2555 | 4.63 | 3.15 | 146,876.60 | -29.24 | -- | -61.16 | -- | 42.08 | -- | -114.45 | -- | 1.21 | -1.23 | 0.3875 | -- | 140.83 | -- | 32.54 | -- | -- | -- |
| Bioventix PLC | 13.61m | 8.10m | 193.65m | 17.00 | 24.27 | 16.13 | 23.59 | 14.23 | 1.53 | 1.53 | 2.57 | 2.30 | 1.01 | 1.57 | 2.26 | 800,387.60 | 59.95 | 58.33 | 67.24 | 63.62 | 93.20 | 93.09 | 59.51 | 64.12 | 7.07 | -- | 0.00 | 90.92 | 6.17 | 7.93 | -3.29 | 6.67 | -28.40 | 16.25 |
| Allergy Therapeutics plc | 55.20m | -40.22m | 247.85m | 635.00 | -- | 66.96 | -- | 4.49 | -0.0107 | -0.0107 | 0.0137 | 0.0008 | 0.8389 | 2.09 | 7.40 | -- | -61.12 | -22.88 | -86.97 | -30.15 | 53.87 | 66.47 | -72.86 | -24.88 | 1.01 | -8.70 | 0.8931 | -- | -7.36 | -5.62 | 6.63 | -- | 1.88 | -- |
| Puretech Health PLC | 371.84k | -65.52m | 389.83m | 90.00 | -- | 1.55 | -- | 1,048.39 | -0.239 | -0.239 | 0.0014 | 1.05 | 0.0007 | -- | 0.2252 | 4,131.56 | -14.13 | 4.92 | -16.35 | 5.94 | -- | -- | -19,222.22 | 352.67 | -- | -- | 0.0728 | 0.00 | -78.68 | -30.64 | -30.47 | -- | -44.10 | -- |
| Oxford BioMedica plc | 97.28m | -142.02m | 436.93m | 834.00 | -- | 6.56 | -- | 4.49 | -1.44 | -1.44 | 0.9642 | 0.6292 | 0.3012 | 4.09 | 4.21 | 136,252.10 | -51.98 | -19.60 | -66.85 | -24.68 | 36.74 | 50.74 | -172.59 | -44.38 | 2.07 | -12.47 | 0.6077 | -- | -36.04 | 6.04 | -302.20 | -- | -0.6307 | -- |
| Genus plc | 668.80m | 7.90m | 1.09bn | 3.44k | 138.59 | 1.98 | 21.98 | 1.62 | 0.1186 | 0.1186 | 10.14 | 8.30 | 0.6569 | -- | 5.84 | 194,475.10 | 0.2357 | 3.30 | 0.2742 | 3.87 | -- | -- | 0.3589 | 4.98 | 1.21 | 93.17 | 0.3487 | 62.72 | -3.03 | 6.48 | -76.28 | 0.2551 | -2.68 | 2.93 |
| Holder | Shares | % Held |
|---|---|---|
| Vulpes Investment Management Pte Ltd.as of 23 Oct 2023 | 8.44m | 8.01% |
| Threadneedle Asset Management Ltd.as of 30 Oct 2024 | 5.36m | 5.09% |
| Liontrust Investment Partners LLPas of 29 Oct 2024 | 5.27m | 5.00% |
| M&G Investment Management Ltd.as of 15 Mar 2023 | 5.07m | 4.81% |
| Global Alpha Capital Management Ltd.as of 15 Mar 2023 | 3.88m | 3.68% |
| BlackRock Investment Management (UK) Ltd.as of 01 Oct 2024 | 3.64m | 3.46% |
| Hargreaves Lansdown Asset Management Ltd.as of 15 Mar 2023 | 3.03m | 2.88% |
| Charles Schwab Investment Management, Inc.as of 03 Sep 2024 | 3.01m | 2.86% |
| The Vanguard Group, Inc.as of 15 Mar 2023 | 2.71m | 2.57% |
| Banque Pictet & Cie SAas of 03 Sep 2024 | 1.92m | 1.82% |
